Routhu et al., 2021 - Google Patents
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungsRouthu et al., 2021
View HTML- Document ID
- 4805326732482537243
- Author
- Routhu N
- Cheedarla N
- Gangadhara S
- Bollimpelli V
- Boddapati A
- Shiferaw A
- Rahman S
- Sahoo A
- Edara V
- Lai L
- Floyd K
- Wang S
- Fischinger S
- Atyeo C
- Shin S
- Gumber S
- Kirejczyk S
- Cohen J
- Jean S
- Wood J
- Connor-Stroud F
- Stammen R
- Upadhyay A
- Pellegrini K
- Montefiori D
- Shi P
- Menachery V
- Alter G
- Vanderford T
- Bosinger S
- Suthar M
- Amara R
- Publication year
- Publication venue
- Immunity
External Links
Snippet
A combination of vaccination approaches will likely be necessary to fully control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we show that modified vaccinia Ankara (MVA) vectors expressing membrane-anchored pre-fusion …
- 229960005486 vaccines 0 title abstract description 119
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Routhu et al. | A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs | |
| Martínez-Flores et al. | SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants | |
| Case et al. | Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice | |
| Winkler et al. | Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection | |
| Lu et al. | A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike | |
| Purushotham et al. | Vaccine platforms for the prevention of Lassa fever | |
| Barry et al. | Protection against mycoplasma infection using expression-library immunization | |
| Coronado et al. | A critical review about different vaccines against classical swine fever virus and their repercussions in endemic regions | |
| Lázaro-Frías et al. | Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins | |
| Zuiani et al. | A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease | |
| Nice et al. | The role of interferon in persistent viral infection: insights from murine norovirus | |
| Acosta-Coley et al. | Vaccines platforms and COVID-19: what you need to know | |
| JP2017515508A (en) | Virus-like vesicle (VLV) based vaccine for preventing or treating chronic hepatitis B virus (HBV) infection | |
| Tregoning et al. | Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines | |
| Jiang et al. | Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy | |
| Mueller et al. | Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses | |
| Müller et al. | Immunity against Lagovirus europaeus and the Impact of the Immunological Studies on Vaccination | |
| Chan et al. | Mutating chikungunya virus non‐structural protein produces potent live‐attenuated vaccine candidate | |
| Perez et al. | A single dose of an MVA vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein neutralizes variants of concern and protects mice from a lethal SARS-CoV-2 infection | |
| Choi et al. | Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review | |
| Johnson et al. | Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection | |
| Sankaradoss et al. | Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences | |
| Saunders et al. | Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model | |
| Chai et al. | Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis | |
| CN106520710B (en) | Preparation and application of recombinant Newcastle disease virus live vector vaccine expressing duck tembusu virus prm and E proteins |